Pooled samples from cohorts 1 and 2 (anti-CCP3(−) Controls = 52 participants, 152 samples; At-Risk = 56 participants, 164 samples; and Early RA = 22 participants, 65 samples) were first split into training and test data sets. This evidence concerns the gene AGBL3 and rheumatoid arthritis.